Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.
Hematology/Oncology March 18th 2024
Cleveland Clinic Journal of Medicine
Explore a compelling case study demonstrating the intricate relationship between chronic myeloid leukemia, autoimmunity, and post-transplant hematologic complications, highlighting the importance of thorough diagnostics and tailored treatment approaches in managing complex patient scenarios.
Hematology March 18th 2024
Oncology Learning Network
Explore the latest findings on vibecotamab’s potential in R/R AML treatment, revealing promising results with an optimized dosing regimen that mitigates cytokine response syndrome while improving patient outcomes.
Hematology/Oncology March 11th 2024
Hematology Advisor
In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.
Hematology February 12th 2024
In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.
Hematology January 22nd 2024
Journal of Clinical Pathways
Dr. Zackon’s study reveals a stark 18% difference in mortality rates between Black and White CLL patients, underscoring the profound impact of socioeconomic factors on patient outcomes.
Hematology/Oncology January 8th 2024